Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab. However, for years the company has been working towards the goal of developing medicines entirely on its own and 2024 was a transformative year in that regard. Now the antibody specialist aims to execute another deal in 2025 that could continue its evolution.
Genmab Has First Wholly Owned Antibodies In Phase III, Hunts For More
Shifting From Out-Licensing To Retaining Assets
CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.
